MOUNTAIN VIEW, Calif., April 24, 2014 /PRNewswire/ -- Based on its recent analysis of the oximetry technology market, Frost & Sullivan recognizes ViOptix, Inc. with the 2013 North American Frost & Sullivan Award for New Product Innovation for the development of the T.Ox Tissue Oximeter. It is a patent-protected, non-invasive, portable device for tissue-oxygen saturation diagnosis and monitoring. The device has broad appeal across various healthcare applications, including plastic/reconstructive surgery, intra- and post-operative tissue oxygen saturation monitoring, melanoma detection, and other critical care procedures.

The T.Ox Tissue Oximeter consists of a touchscreen display console that makes it user-friendly in various healthcare settings, including medical testing facilities and surgical areas. It aids the early detection of several tissue-related medical conditions, enabling healthcare providers to determine appropriate treatment options.

The T.Ox Tissue Oximeter leverages near-infrared (NIR) technology to assess tissue health by measuring photon scattering and absorption ratios. This way, it delivers continuous, real-time, tissue-oxygen saturation data to physicians and surgeons, helping them with both diagnosis and treatment. The use of NIR technology also eliminates the need for risky, invasive medical testing procedures that can be costly and increase patient exposure to infectious diseases.

"From an economic perspective, the use of a single device for diagnosing multiple tissue-related illnesses and improving surgical procedure effectiveness essentially delivers a strong economic value proposition," said Frost & Sullivan Research Analyst Imran Khan. "In addition, ViOptix offers its product on a leased basis to hospitals and other microsurgical centers, which reduces the strain on these organizations' capital expenditures."

From a healthcare providers' perspective, the T.Ox Tissue Oximeter solution aids effective diagnosis and treatment of various vascular conditions. It can benefit a wide variety of medical procedures, including breast reconstructive surgeries after a mastectomy, plastic surgery, detection and assessment of peripheral vascular disease, melanoma detection and treatment, and amputation.

"Unlike other tissue oximetry products that are still in trial stages, ViOptix received Food and Drug Administration approval for its first-generation Tissue Oximeter product T.Ox in 2005," noted Khan. "Therefore, the company has first-mover advantage as a leading provider of a tissue oximetry solution that fits the diagnostic and treatment needs of a wide spectrum of healthcare providers."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ViOptix

ViOptix Inc. develops, manufactures and markets innovative proprietary products for improving surgical outcomes through the non-invasive measurement of localized oxygen saturation levels in tissue. Its first product, the T.Ox Tissue Oximeter, received U.S. Food and Drug Administration clearance in January 2005.  For more information on the Company or its products, visit the Company's website at www.vioptix.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Mark Lonsinger
E: lonsingerm@vioptix.com

SOURCE Frost & Sullivan